RUVBL1-AS1: A Potential Drug Target and Biomarker (G100874089)

Target Name: RUVBL1-AS1

NCBI ID: G100874089

RUVBL1-AS1

Other Name(s): RUVBL1 antisense RNA 1

RUVBL1-AS1: A Potential Drug Target and Biomarker

Ribosomal RNA binding protein (RNP) family member 1 (RUVBL1) is a protein that plays a crucial role in the regulation of gene expression in various organisms, including humans. The RNP family is a large transmembrane protein family that includes 21 different proteins, including RUVBL1, which is composed of four distinct subunits (RUVBL1-AS1, RUVBL1-AS2, RUVBL1-AS3, and RUVBL1-AS4). RUVBL1 is widely expressed in various tissues and cells, including muscle, liver, brain, and placenta, and has been implicated in the regulation of various cellular processes, including cell growth, apoptosis, and transcriptional regulation [2,3].

Recent studies have identified RUVBL1 as a potential drug target due to its involvement in various cellular processes that are important for human health and disease. RUVBL1 has been shown to play a role in the regulation of cell adhesion, which is critical for the development and maintenance of tissues and organs [4,5]. RUVBL1 has also been implicated in the regulation of cell survival and proliferation, which are important for the development and progression of cancer [6,7]. In addition, RUVBL1 has been shown to be involved in the regulation of inflammation, which is a crucial aspect of many diseases, including cancer and cardiovascular disease [8,9].

The identification of RUVBL1 as a potential drug target has led to the development of small molecule inhibitors that can inhibit RUVBL1 function. These inhibitors have been shown to have a range of therapeutic effects, including the inhibition of cancer cell growth, the inhibition of cell adhesion, and the inhibition of cell survival [10,11].

In addition to its potential as a drug target, RUVBL1 has also been identified as a potential biomarker for several diseases. The RNP family is known for its ability to interact with various RNA molecules, including microRNAs (miRNAs). This interaction between RNP and RNA has led to the proposal that RNP-mediated regulation of gene expression could be used as a biomarker for various diseases.

One of the key challenges in the development of RUVBL1-based biomarkers is the difficulty in accessing the RNP-bound RNA molecules. The RNP is a large protein that can interact with a wide range of RNA molecules, making it difficult to isolate and purify RNA from the complexed RNP-protein interactions. However, recent advances in technology, such as RNA sequencing (RNA-seq) and mass spectrometry (MS), have enabled the identification of RNA molecules that are bound to RNP and can be used as biomarkers [13,14].

In conclusion, RUVBL1 is a protein that has the potential to be a drug target and biomarker. The identification of RUVBL1 as a potential drug target has led to the development of small molecule inhibitors that have been shown to have a range of therapeutic effects. In addition, the identification of RUVBL1 as a potential biomarker has the potential to revolutionize our understanding of disease mechanisms and the development of new diagnostic tests. Further research is needed to fully understand the role of RUVBL1 in various cellular processes and to develop effective biomarkers for diseases associated with RUVBL1 dysfunction.

Protein Name: RUVBL1 Antisense RNA 1

The "RUVBL1-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RUVBL1-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets